Search
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A193272,A193275,L12648] Avastin was subsequently approved by Health Canada on March 24, 2010 and by the European Commission on April 21, 2021. … for intravitreal injection, which received European Commission and MHRA marketing authorization in 2024 and FDA approval on July 24, 2026 for the treatment of wet AMD.
Categories: Complex MixturesProducts: ABXEDA EDiethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawnA synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. … (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Synonyms: (E)-3,4-bis(4-hydroxyphenyl)-3-hexene, α,α'-diethyl-(E)-4,4'-stilbenediolCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigational[A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L23524] In November 2021, the same indication was approved by the EMA.
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalFDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.
Varicella zoster vaccine (recombinant)
go.drugbank.com/drugs/DB13924ApprovedInvestigationalThe main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). … Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in
Synonyms: gE recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein EElinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigationalin thermo-regulation. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved
Synonyms: 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide, Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Fenretinide
go.drugbank.com/drugs/DB05076InvestigationalA synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(4-hydroxyphenyl)all-trans retinamideCenegermin
go.drugbank.com/drugs/DB13926ApprovedInvestigationalIt received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines